{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:41:35Z","timestamp":1780580495713,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ad.2021.12.014","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T10:32:20Z","timestamp":1640255540000},"page":"674-684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Nemolizumab: un innovador tratamiento biol\u00f3gico para el control de la interleuquina 31 (IL-31) clave en la dermatitis at\u00f3pica y el prurigo nodular"],"prefix":"10.1016","volume":"113","author":[{"given":"E.","family":"Serra-Baldrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"Santamar\u00eda-Bab\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Francisco Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2021.12.014_bib0220","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet. London, England"},{"key":"10.1016\/j.ad.2021.12.014_bib0225","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/1346-8138.13392","article-title":"Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016","volume":"43","author":"Saeki","year":"2016","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2021.12.014_bib0230","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","author":"Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatology Venereol."},{"issue":"8\u20139","key":"10.1016\/j.ad.2021.12.014_bib0235","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.annder.2020.04.010","article-title":"Clinical characteristics of patients with prurigo nodularis: A descriptive study","volume":"147","author":"Reverte","year":"2020","journal-title":"Ann Dermatol Venereol."},{"key":"10.1016\/j.ad.2021.12.014_bib0240","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jdv.14570","article-title":"European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatology Venereol."},{"key":"10.1016\/j.ad.2021.12.014_bib0245","doi-asserted-by":"crossref","first-page":"639097","DOI":"10.3389\/fmed.2021.639097","article-title":"Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front Med."},{"key":"10.1016\/j.ad.2021.12.014_bib0250","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-030-55617-4_8","article-title":"Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment. In: Advances in Experimental Medicine and Biology","volume":"1290","author":"Rook","year":"2021","journal-title":"Adv Exp Med Biol;"},{"issue":"JUN.","key":"10.1016\/j.ad.2021.12.014_bib0255","article-title":"Role of the pruritic cytokine IL-31 in autoimmune skin diseases","volume":"10","author":"Gibbs","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0260","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/exd.13533","article-title":"Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis","volume":"27","author":"Nakashima","year":"2018","journal-title":"Exp Dermatol."},{"key":"10.1016\/j.ad.2021.12.014_bib0265","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: A new key player in dermatology and beyond","volume":"141","author":"Ba\u011fci","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0270","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/jcm10091906","article-title":"Interleukin-31 and Pruritic Skin","volume":"10","author":"Furue","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.ad.2021.12.014_bib0275","first-page":"8","article-title":"Interleukin-31 as a Clinical Target for Pruritus Treatment","author":"Kabashima","year":"2021","journal-title":"Front Med."},{"key":"10.1016\/j.ad.2021.12.014_bib0280","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2021.12.014_bib0285","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0290","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","article-title":"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis","volume":"117","author":"Bilsborough","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0295","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol."},{"issue":"1\u20132","key":"10.1016\/j.ad.2021.12.014_bib0300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.vetimm.2013.10.017","article-title":"Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells","volume":"157","author":"McCandless","year":"2014","journal-title":"Vet Immunol Immunopathol."},{"key":"10.1016\/j.ad.2021.12.014_bib0305","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: Receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0310","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cea.12875","article-title":"Human basophils are a source of - and are differentially activated by - IL-31","volume":"47","author":"Raap","year":"2017","journal-title":"Clin Exp Allergy."},{"key":"10.1016\/j.ad.2021.12.014_bib0315","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.neuroscience.2006.07.009","article-title":"Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns","volume":"142","author":"Bando","year":"2006","journal-title":"Neuroscience."},{"key":"10.1016\/j.ad.2021.12.014_bib0320","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuroscience.2013.07.035","article-title":"Neural processing of itch","volume":"250","author":"Akiyama","year":"2013","journal-title":"Neuroscience."},{"key":"10.1016\/j.ad.2021.12.014_bib0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.anai.2020.05.028","article-title":"New and emerging treatments for inflammatory itch","volume":"126","author":"Erickson","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0330","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell."},{"key":"10.1016\/j.ad.2021.12.014_bib0335","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaci.2019.06.031","article-title":"Selective role of neurokinin B in IL-31-induced itch response in mice","volume":"144","author":"Sakata","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0340","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1111\/bph.12823","article-title":"Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice","volume":"171","author":"Kasutani","year":"2014","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.ad.2021.12.014_bib0345","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0350","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/intimm\/dxq027","article-title":"Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis","volume":"22","author":"Cheung","year":"2010","journal-title":"Int Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.03.050","article-title":"Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation","volume":"132","author":"Stott","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0360","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nri3049","article-title":"Homeostatic chemokine receptors and organ-specific metastasis","volume":"11","author":"Zlotnik","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0365","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","article-title":"Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma","volume":"59","author":"Yaseen","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ad.2021.12.014_bib0370","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/vde.12682","article-title":"A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA","volume":"29","author":"Souza","year":"2018","journal-title":"Vet Dermatol"},{"key":"10.1016\/j.ad.2021.12.014_bib0375","author":"Mikhak","year":"2018","journal-title":"First-in- human study of KPL-716, anti-oncostatin M receptor beta monoclonal antibody, in healthy volunteers and subjects with atopic dermatitis. 27th Congress of the European Academy of Dermatology and Venereology, Paris, France, September12-16"},{"key":"10.1016\/j.ad.2021.12.014_bib0380","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2021.12.014_bib0385","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti\u2013Interleukin-31 Receptor A Antibody for Atopic Dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2021.12.014_bib0390","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0395","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0400","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/1346-8138.14934","article-title":"Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study","volume":"46","author":"Mihara","year":"2019","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2021.12.014_bib0405","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2021.12.014_bib0410","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2021.12.014_bib0415","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/jcph.969","article-title":"Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation","volume":"57","author":"Saito","year":"2017","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.ad.2021.12.014_bib0420","doi-asserted-by":"crossref","first-page":"190","DOI":"10.18176\/jiaci.0672","article-title":"Efficacy and safety of nemolizumab for treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials","volume":"31","author":"Xiao","year":"2021","journal-title":"J Investig Allergol Clin Immunol."},{"key":"10.1016\/j.ad.2021.12.014_bib0425","article-title":"Time to meaningful clinical response in reduction of itch in atopic dermatitis","author":"Lin","year":"2020","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.ad.2021.12.014_bib0430","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti\u2013Interleukin-31 Receptor A Antibody for Atopic Dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731021004798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731021004798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:12:28Z","timestamp":1757553148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731021004798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0001731021004798"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2021.12.014","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nemolizumab: un innovador tratamiento biol\u00f3gico para el control de la interleuquina 31 (IL-31) clave en la dermatitis at\u00f3pica y el prurigo nodular","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2021.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}